Tags

Type your tag names separated by a space and hit enter

Focus on ziprasidone.
Curr Med Res Opin. 2001; 17(2):146-50.CM

Abstract

Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The initial evidence suggests an effective dosage range of 80-160 mg/day. Clinical trials suggest that the drug is an effective antipsychotic in schizophrenia and schizoaffective disorder with a beneficial effect on negative symptoms and symptoms of depression. The main adverse effects appear to be somnolence (14%) and nausea (10%). Ziprasidone has relatively fewer side-effects and yet has at least equivalent efficacy for florid 'positive' symptoms compared with conventional antipsychotics. The additional serotonergic actions deliver further efficacy against 'negative' and affective symptoms of schizophrenia. Reduced effects on cognitive abilities compared to conventional antipsychotics make ziprasidone more attractive still. Barring any unforeseen complications, it appears to a most valuable addition to the antipsychotic agents.

Authors+Show Affiliations

Halton Hospital and the University of Liverpool, Liverpool, UK. bengreen@liverpool.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11759185

Citation

Green, B. "Focus On Ziprasidone." Current Medical Research and Opinion, vol. 17, no. 2, 2001, pp. 146-50.
Green B. Focus on ziprasidone. Curr Med Res Opin. 2001;17(2):146-50.
Green, B. (2001). Focus on ziprasidone. Current Medical Research and Opinion, 17(2), 146-50.
Green B. Focus On Ziprasidone. Curr Med Res Opin. 2001;17(2):146-50. PubMed PMID: 11759185.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Focus on ziprasidone. A1 - Green,B, PY - 2002/1/5/pubmed PY - 2002/9/26/medline PY - 2002/1/5/entrez SP - 146 EP - 50 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 17 IS - 2 N2 - Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The initial evidence suggests an effective dosage range of 80-160 mg/day. Clinical trials suggest that the drug is an effective antipsychotic in schizophrenia and schizoaffective disorder with a beneficial effect on negative symptoms and symptoms of depression. The main adverse effects appear to be somnolence (14%) and nausea (10%). Ziprasidone has relatively fewer side-effects and yet has at least equivalent efficacy for florid 'positive' symptoms compared with conventional antipsychotics. The additional serotonergic actions deliver further efficacy against 'negative' and affective symptoms of schizophrenia. Reduced effects on cognitive abilities compared to conventional antipsychotics make ziprasidone more attractive still. Barring any unforeseen complications, it appears to a most valuable addition to the antipsychotic agents. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/11759185/Focus_on_ziprasidone_ L2 - https://medlineplus.gov/psychoticdisorders.html DB - PRIME DP - Unbound Medicine ER -